Tech Company Financing Transactions
Gliknik Funding Round
On 10/9/2012, Gliknik raised $4.9 million in Series B investment from Baxter Ventures and private investors.
Transaction Overview
Company Name
Announced On
10/9/2012
Transaction Type
Venture Equity
Amount
$4,900,000
Round
Series B
Investors
Baxter Ventures (Lead Investor)
Proceeds Purpose
With the funding, Gliknik will further advance towards the clinic its IVIG-mimetic lead compound, GL-2045, from its first-in-class stradomer platform. Gliknik will study the compound in autoimmune conditions, including initially Myasthenia gravis (a neuromuscular disorder) and a variety of other neurological indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
801 West Baltimore St. 501A
Baltimore, MD 21201
USA
Baltimore, MD 21201
USA
Phone
Website
Email Address
Not Recorded
Overview
Gliknik develops therapies for patients with cancer and immune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Block
Vice President
Henrik Olsen
VP - Bus. Development
Jeffrey Herpst
Browse more venture capital transactions:
Prev: 10/9/2012: Zenoss venture capital transaction
Next: 10/9/2012: FSAStore venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs